Gina Bartes
63 posts
#Avicii 6 years ago today.
Attendees versus AI tonight at the @novonordisk sponsored event with @DrLoomba and @AlinaAllenMD chairing the info packed session at #DDW2024! AI actually did very well comparing responses about the best ways to manage MASLD/MASH patients.
So good to be at #TLM2023 in Boston with the @AASLDtweets @AASLDPresident community. @VWSWong doing a masterful job discussing new treatments for #MASH. @NoureddinMD @marurinella @LiverArizona @gbartes @mcharltonmd @Pinnacle_TX @MadrigalPharma @novonordiskmed
Very important virtual meeting with the FDA today re: trial design in NASH. Day 2 tomorrow should be very interesting, happy to be part of this critical conversation. Link to register for day 2 below. @NoureddinMD @LiverArizona @anitakohli @gbartes fda.yorkcast.com/webcast/Login/…
Happy to represent @AASLDtweets and @OHIOLIVER at this important webinar on the new steatotic liver disease SLD nomenclature. @marurinella @NoureddinMD @JonathanStineMD @LiverArizona @gbartes @anitakohli @AlinaAllenMD @schattenbergJ @JVLazarus
If you are wondering about the future of NAFLD/MASLD the @TheLancet has published data showing that 1.31 Billion People could be living with T2DM by 2050!! #LiverTwitter @AlkhouriNaim @marurinella @AASLDtweets @AmerGastroAssn @WRayKimMD @ChengHanNg pubmed.ncbi.nlm.nih.gov/37356446/
The NAIL NIT consortium is here and will help shape the future of #NASH Trials. Credit to @NoureddinMD for getting this started and leading the way. @schattenbergJ @phil_newsome7 @AlinaAllenMD @JonathanStineMD @novonordiskmed @TernsPharma @MadrigalPharma @Pinnacle_TX
NAFLD Article of the Week @IUGastro AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease pubmed.ncbi.nlm.nih.gov/36727674/ ⏺️ Fantastic guidance @marurinella @DrLoomba and colleagues
#HCPs: @CDCgov recommends universal #HepatitisC screening for: • ALL adults at least once in their lifetime • pregnant people during EACH pregnancy Read CDC’s testing recommendations here: bit.ly/3zkx6zy
